Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

PARP Inhibition in Prostate Cancer: An Evolving Paradigm and the Role of the Practicing Urologist
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: November 30, 2022 Expiration: November 29, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
person default
Stephen Freedland, MD
Rana R. McKay, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the medical need and rationale for PARP inhibitors and PARP inhibitor–based combinations in prostate cancer, with or without DNA damage repair alterations
  • Obtain tumor tissue and assure that it is tested for DNA damage repair alterations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer
  • Appraise the available clinical evidence and clinical trial strategies using PARP inhibitor–based combinations for prostate cancer in metastatic and earlier stages of disease with or without DNA damage repair alterations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor combinations in prostate cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Stephen Freedland, MD

Professor
Department of Surgery
Department of Urology
Cedars-Sinai Medical Center
Los Angeles, California
Staff Physician
Durham VA Medical Center
Durham, North Carolina

Stephen Freedland, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exact Sciences, Janssen, Merck, Myovant, Pfizer, Sanofi, Tempus.
Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento, Tempus; researcher: AstraZeneca, Bayer, Tempus.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors and recent findings into the treatment of patients with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 30, 2022, through November 29, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

PARP Inhibition in Prostate Cancer: An Evolving Paradigm and the Role of the Practicing Urologist
  • CME

Loading...
In this on-demand webcast from a live webinar, an expert urologist and oncologist discuss testing strategies, the latest data on monotherapy and combination therapy with PARP inhibitors in prostate cancer, and identifying patients eligible for ongoing clinical trials.
person default
Stephen Freedland, MD
Rana R. McKay, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: November 30, 2022 Expiration: November 29, 2023

Related Content

On-demand webcast: Brenda Martone, MSN, ANP-BC, AOCNP, on best nursing practices for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Brenda Martone, MSN, ANP-BC, AOCNP Registered Nurses: 0.75 Nursing contact hours Released: November 3, 2022 Expired: November 2, 2023

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director
person default Brenda Martone, MSN, ANP-BC, AOCNP
Program Director
Released: October 19, 2022

Slides for urologists on single-agent and combination PARP inhibitor therapy for metastatic prostate cancer, from Clinical Care Options (CCO)

Rana R. McKay, MD Released: October 17, 2022

person default Stephen Freedland, MD Released: October 17, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings